What Kineticos Life Sciences does

Kineticos Life Sciences is a privately held life sciences investment and consulting firm founded in 2007 by Shailesh Maingi and headquartered in Raleigh, North Carolina (Research Triangle Park area). The firm operates a dual-platform business model that combines capital deployment through multiple investment vehicles with strategic consulting services to biotech, CDMO, and medtech companies across the US, UK, and Scotland.

The firm's investment platform consists of three dedicated funds plus a company-creation engine. The Kineticos Disruptor Fund Series targets oncology, neurosciences, and rare diseases through modalities including cell therapy, gene therapy, gene editing, RNAi, and immuno-oncology. The Kineticos AMR Accelerator Fund I (KAMRA I), launched in 2023, is dedicated to antimicrobial resistance. The Kineticos Capital Partners Fund invests in specialized pharma services, tools, and equipment companies. The Kineticos Foundry is a proprietary company-creation model that licenses technologies from R1 universities (including Harvard's Myers Lab) and assembles operating teams from Kineticos' advisor network to build new companies such as Kinvard Bio and Kincell Bio before they reach the market. As of December 31, 2024, Kineticos managed approximately $115 million in assets under management, with $75M+ deployed across 13 portfolio companies since beginning investment activities in 2019; Disruptor Fund II closed in November 2023 with $57.3 million in committed capital.

Kineticos generates revenue through fund management fees and carried interest from its investment vehicles, alongside fee-for-service, hybrid fee-for-service/success-based, and equity-based consulting engagements covering strategy, business development, market access, operational excellence, and M&A support. The firm is led by Shailesh Maingi (Founder and Managing Partner), Philip Gialenios (President and COO), Frank Lis (President and CEO of Kineticos Ventures), and senior venture partners including Mark Bamforth (founder of three successful CDMOs: Arranta Bio, Brammer Bio, Gallus Bio), Lloyd Payne (former Evotec EVP), Steve Gelone, and Richard Snyder. Notable realized outcomes include Arranta Bio's acquisition by Recipharm (April 2022), Amylyx's IPO (AMLX), neuro42's FDA 510(k) clearance, and Inceptor Bio dosing its first patient in the IB-T101 clinical trial for clear cell Renal Cell Carcinoma.

Name

Kineticos Life Sciences

Legal name

Kineticos Life Sciences

Website

https://kineticos.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Kineticos Life Sciences is a life sciences investment and consulting firm managing ~$115M across funds targeting oncology, neurosciences, AMR, and pharma services. Founded 2007 in Raleigh, NC, it deploys capital and strategic advisory to biotech and medtech companies.

Ownership category

akta.pro rank

Product category

Life Sciences Investment & Consulting

NAICS

Other Scientific and Technical Consulting Services (54169)

SIC

Services-Business Services, Nec (7389)

akta.pro primary industry

Instrumentation, Controls & Automation Engineering Consulting (BPAHAIAM)

Keywords

• Life sciences consulting
• Venture capital funds
• Biotech investment management
• Company creation platform
• Pharma advisory services

Headquarters

HQ city

Morrisville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Investment Management: Kineticos generates returns through managing investment vehicles including Kineticos Disruptor Fund I and II (targeting oncology, neuroscience, rare diseases), and KAMRA I (antimicrobial resistance). Returns come from equity appreciation and exits from portfolio companies.
2. Strategic Consulting Services: Kineticos provides consulting services to life sciences companies across strategy, business development, licensing, market access, and operational excellence. Revenue is generated through fee-for-service, hybrid fee/success-based arrangements, and equity arrangements.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Kineticos is a life sciences investment and consulting firm that operates multiple dedicated investment funds (Kineticos Capital Partners Fund, Kineticos Disruptor Fund Series, KAMRA I AMR Accelerator Fund) targeting oncology, neurosciences, rare diseases, antimicrobial resistance, and pharma services/tools/equipment. The firm also provides strategic advisory and consulting services to life sciences companies and operates a Foundry platform that in-licenses technologies from R1 universities to create and build new companies.

Product overview

Kineticos Life Sciences is a life sciences investment and consulting firm that operates as a unified platform combining capital deployment and operational expertise. The core offerings include three distinct investment funds—the Kineticos Capital Partners Fund (specialized pharma services/tools/equipment), the Kineticos Disruptor Fund Series (oncology/neurosciences/rare diseases), and the Kineticos AMR Accelerator Fund I (KAMRA I for antimicrobial resistance)—alongside the Kineticos Foundry for company creation. The firm provides consulting services to support portfolio companies across strategy, business development, and operational execution. These components work together as an integrated ecosystem where the investment funds provide capital, the Foundry identifies and builds new companies from university technologies, and consulting services support portfolio company growth.

Differentiator

Problem solved

Functional benefit

Brands

• Kineticos Capital Partners Fund: Investment fund powering the innovative life sciences ecosystem by investing in specialized pharma services, tools and equipment companies
• Kineticos Disruptor Fund
• Kineticos AMR Accelerator Fund
• Kineticos Foundry

Products and services

• Kineticos Capital Partners Fund

Quantifiable outcome

• Portfolio company Arranta Bio acquired by Recipharm for undisclosed amount
• +3 more outcomes

Named customers12 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core.

• GRIT BiocoreStrategic or Co-development Partner · 18 December 2024Inceptor Bio (Kineticos portfolio company) entered strategic partnership with GRIT Bio for IB-T101 CAR-T therapy. GRIT Bio received exclusive license for IB-T101 in China and will oversee development, manufacturing, and commercialization.
• INCATE (Incubator for Antibacterial Therapies in Europe)coreStrategic or Co-development Partner · 6 December 2023Kineticos AMR Accelerator Fund I (KAMRA I) partnered with INCATE to support early-stage AMR innovators. INCATE brings together translational research, industry, entrepreneurs, and investors. Kineticos provides R&D and strategic support to INCATE ventures and Dr. Richard Snyder joined the INCATE Selection Committee. Partnership extended in December 2024.
• Eos AdvisorycoreStrategic or Co-development Partner · 24 February 2021Strategic partnership between Kineticos Disruptor Fund and St Andrews-based Eos Advisory to co-invest in early-stage Scottish life sciences companies. Aim to invest more than £10m over five years in oncology-focused firms.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Back Bay Life Science Advisors: Boston-based life sciences consulting firm offering strategy, business development, and transaction advisory to biotechs and investors — directly comparable to Kineticos's consulting practice with similar therapeutic area focus.
• Locust Walk: Life sciences transaction advisory and investment bank serving biotechs and pharma — comparable operating model combining strategic advisory with deep industry relationships in the same therapeutic verticals as Kineticos.
• Health Advances: Specialized life sciences strategy consulting firm serving pharma, biotech, and medtech clients on commercial strategy, licensing, and M&A — closest functional peer to Kineticos's consulting arm in scope and customer base.
• Triangle Insights Group: Life sciences consulting firm serving biotech and pharma clients on commercial strategy, market access, and asset diligence — also Durham, NC-based and overlapping with Kineticos on therapeutic focus and client profile.
• NewSpring Capital: Lower-middle-market PE firm with a dedicated healthcare strategy, co-led Kincell Bio's $22M round with Kineticos — operates in overlapping healthcare verticals (CDMOs, life sciences services) at a different fund scale.
• MVM Partners: Healthcare growth equity firm investing since 1997, co-led eXmoor's $35M Series A with Kineticos Ventures — comparable late-stage investor in cell/gene therapy CDMOs and life sciences services companies.

Broad incumbents

• Atlas Venture: Established life sciences-focused venture firm that both invests in and helps build biotech companies — broader and more capital-rich than Kineticos, but operating a similar model of early-stage therapeutic company creation.
• OrbiMed: One of the largest healthcare-dedicated investment firms globally, spanning venture, growth, and credit across therapeutics, devices, and CDMOs — Kineticos overlaps on therapeutic focus and CDMO/services investing, though at far smaller scale.
• Cello Health (now Ashfield Health): Acquired Defined Health and similar life sciences advisory firms — broader strategic consulting competitor with established presence in biotech commercial strategy, licensing, and market access that overlaps with Kineticos's offerings.
• RA Capital Management: Healthcare-focused crossover investor with research-driven thesis generation — comparable to Kineticos's research-intensive approach (Disruptor26, Kineticos Research Institute) but operating at substantially larger AUM scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/kineticos
• Xx.com/kineticos

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kineticos Life Sciences